Search details
1.
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Blood
; 142(26): 2327-2331, 2023 12 28.
Article
in English
| MEDLINE | ID: mdl-37738563
2.
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Blood
; 139(13): 1999-2010, 2022 03 31.
Article
in English
| MEDLINE | ID: mdl-34780623
3.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica
; 109(2): 553-566, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-37646664
4.
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.
Hematol Oncol
; 42(3): e3278, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38726682
5.
Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies.
Acta Haematol
; 2024 Jun 01.
Article
in English
| MEDLINE | ID: mdl-38824917
6.
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Oncologist
; 28(3): 199-207, 2023 03 17.
Article
in English
| MEDLINE | ID: mdl-36648324
7.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Am J Hematol
; 98(2): 300-308, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36588409
8.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
J Natl Compr Canc Netw
; 20(4): 322-334, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35390768
9.
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Blood
; 133(11): 1201-1204, 2019 03 14.
Article
in English
| MEDLINE | ID: mdl-30692121
10.
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Haematologica
; 106(6): 1608-1615, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-32414849
11.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Article
in English
| MEDLINE | ID: mdl-34407608
12.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-34196165
13.
Transducin ß-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
Haematologica
; 106(11): 2927-2939, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-33054136
14.
Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy.
J Natl Compr Canc Netw
; 19(9): 1027-1036, 2021 03 26.
Article
in English
| MEDLINE | ID: mdl-33770752
15.
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Am J Hematol
; 96(11): 1374-1384, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-34324220
16.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol
; 21(7): 978-988, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32511983
17.
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
Cancer
; 126(6): 1235-1242, 2020 03 15.
Article
in English
| MEDLINE | ID: mdl-31821549
18.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer
; 126(2): 293-303, 2020 01 15.
Article
in English
| MEDLINE | ID: mdl-31568564
19.
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy.
Br J Haematol
; 189(2): 313-317, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31804715
20.
Does TRIANGLE take down transplantation in mantle cell lymphoma?
Lancet
; 403(10441): 2264-2265, 2024 May 25.
Article
in English
| MEDLINE | ID: mdl-38705162